aspirin / Generic mfg. - LARVOL DELTA

Retraction notice to "Evaluation of the effectiveness of low-dose aspirin and omega 3 in treatment of asymmetrically intrauterine growth restriction: A randomized clinical trial" [Eur. J. Obstet. Gynecol. Reprod. Biol. 210 (2017) 231-235]. (PubMed, Eur J Obstet Gynecol Reprod Biol) - No abstract available

Clinical

"PIK"ing the right patients for adjuvant aspirin therapy for colorectal cancer. (PubMed, Clin Cancer Res) - "However, randomized controlled trial data are lacking. Here, we discuss the SAKK41/13 adjuvant aspirin randomized controlled trial results in context of other adjuvant aspirin trials and emerging data on potential mechanisms of action."

Journal • Colorectal Cancer • Oncology • Solid Tumor • PIK3CA

Haemochromatosis Genotypes and Incident Dementia in a Prospective Study of Older Adults. (PubMed, Neurology) - "Among initially healthy older adults, HFE p.His63Asp homozygosity was associated with a higher risk of incident dementia in men but not women. These findings highlight a potential sex-specific genetic risk factor for dementia and warrant further research into the underlying mechanisms linking p.His63Asp and dementia."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia

Clinical outcomes with the use of aspirin versus clopidogrel as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation. (PubMed, Eur Heart J Cardiovasc Pharmacother) - "In patients with AF receiving double antithrombotic therapy after PCI, aspirin and clopidogrel showed similar efficacy and safety when used in combination with DOAC."

Clinical data • Journal • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Ischemic stroke • Myocardial Infarction

Natural History of Popliteal Artery Aneurysm: Evaluating Percent Thrombus and Size Threshold for Operative Management. (PubMed, J Am Coll Surg) - "These results suggest that size thresholds for PAA repair may warrant reconsideration. Percent thrombus burden may serve as additional criteria for identifying high risk PAAs that warrant operative repair."

Journal • Cardiovascular • Peripheral Arterial Disease • Thrombosis

THE CLINICAL CHARACTERISTICS AND 2-YEAR FOLLOW-UP OF TAKAYASU ARTERITIS PATIENTS WITH PULMONARY ARTERY INVOLVEMENT (EULAR 2025) - "The treatments for TAK were immunosuppressives (IS) in 62 (86.1%), biological treatment in 25 (34.7%), glucocorticoids (GC) in 30 (41.7%), and acetylsalicylic acid (ASA) in 50 (69.4%) patients... In this study, PAI was present in 18.1% of TAK patients, and the presence of pulmonary symptoms, higher ESR and CRP values, and lower ASA use were significantly associated with PAI."

Clinical • Cardiovascular • Hematological Disorders • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Thrombosis • Vasculitis

PHARMACOLOGICAL APPROACHES TO PACNS: REPORT OF TWENTY-FIVE CASES FROM A SINGLE ITALIAN CENTER (EULAR 2025) - "Induction therapy uses steroids and immunosuppressive agents, like cyclophosphamide (CYC), whereas maintenance therapy includes prednisone tapering and azathioprine (AZA) or mycophenolate mofetil (MMF). Rituximab (RTX) and mycophenolate mofetil (MMF) could be good strategies in those who do not respond to initial treatment or have relapses during follow-up...Eight patients (32%) were treated with acetylsalicylic acid and 8 more patients (32%) with antiepileptics... This study concerning twenty-five patients in a monocentric cohort showed different therapeutic approaches on this rare disease. Outcomes of patients are variable and affected by radiological patterns. Furthermore, our results suggest that RTX might be a valid alternative treatment for those patients that are refractory to high dose corticosteroids and CYC."

Clinical • Cardiovascular • CNS Disorders • Depression • Hematological Disorders • Inflammation • Psychiatry • Rare Diseases • Vasculitis

RETROSPECTIVE OBSERVATIONAL STUDY OF OBSTETRIC OUTCOMES IN PATIENTS WITH UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE COMPARED TO SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER STUDY (EULAR 2025) - "Multivariable analysis showed that acetylsalicylic acid (ASA) use reduced the risk of miscarriage in UCTD patients (OR: 0.06, 95% CI: 0.01–0.46)... In UCTD patients, ASA use decreases the risk of miscarriage, whereas anti-Ro antibodies increase complications, as do anti-dsDNA antibodies in SLE patients. These findings underscore the importance of multidisciplinary management in UCTD and SLE patients, with special attention to immunological profiles. Further studies are needed to identify and evaluate other risk factors associated with AOEs in these conditions."

Observational data • Retrospective data • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Obstetrics • Rheumatology • Systemic Lupus Erythematosus

CARDIOVASCULAR OUTCOMES AND MORTALITY ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS IN INFLAMMATORY MYOSITIS AND NECROTIZING MYOPATHY: A RETROSPECTIVE COHORT STUDY (EULAR 2025) - "The cohort with GLP-1 RA use (n = 3,066) included patients treated with Exenatide, Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, or Lixisenatide, while the comparator cohort without GLP-1 RA use (n = 57,788) included patients not receiving these therapies. Propensity score matching (PSM) was conducted to adjust for baseline differences, including demographics (age, sex, ethnicity), comorbidities (hypertension, diabetes, obesity, smoking), and medication use (statins, insulin, corticosteroids, SGLT2 inhibitors, methotrexate, rituximab)...Comorbidities such as hypertension (73.6% vs. 25.8%), diabetes (71.1% vs. 14.4%), and obesity were more prevalent, and medication use, including aspirin (44.2%) and metformin (56.8%), was also higher... GLP-1 RA is associated with significant reductions in mortality and cardiovascular events in patients with inflammatory myositis and necrotizing myopathy. These findings suggest that GLP-1 RAs may be a valuable adjunctive therapy for..."

Retrospective data • Cardiovascular • Dermatomyositis • Diabetes • Genetic Disorders • Hypertension • Immunology • Inflammation • Metabolic Disorders • Myocardial Infarction • Myositis • Obesity • Venous Thromboembolism

PREGNANCY OUTCOMES IN IDIOPATHIC INFLAMMATORY MYOPATHIES: A NATIONAL MULTICENTRIC STUDY FROM PORTUGAL (EULAR 2025) - "Conventional disease-modifying antirheumatic drugs (DMARDs) were prescribed in 8 patients, namely azathioprine prescribed to 5 (2 DM, 2 overlapping syndromes and 1 PM) and hydroxychloroquine to 6 (3 overlapping syndromes, 2 DM and 1 IMNM). Rituximab and cyclosporine were prescribed for a patient with ASS, and intravenous immunoglobulin for a patient with DM. One patient with ASS had an unplanned pregnancy while on mycophenolate mofetil and cyclophosphamide with a subsequent early miscarriage...Low-dose aspirin was prescribed to 5 patients... This study highlights the increased risk of APOs in women with IIM, particularly those with uncontrolled disease at conception. Special attention should be given to ASS patients with high titers of anti-Jo1, considering other cases of late fetal demise described in the literature. Achieving effective disease control with pregnancy-compatible drugs is critical for improving obstetric outcomes."

Clinical • Dermatology • Dermatomyositis • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Myositis • Obstetrics • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis

OLDER PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME PRESENTING WITH ARTERIAL THROMBOSIS ARE AT RISK TO DEVELOP SMALL VESSEL INVOLVEMENT (EULAR 2025) - "The remaining 2 were on low-dose aspirin (LDA): one due to asymptomatic microvascular CNS disease; the other one had ION but was non-compliant to anticoagulation due to a psychiatric disorder... Around one in seven patients in our APS cohort had SV occlusions, which warrant prompt diagnosis and treatment. Our data suggest that particular attention should be given to these manifestations in older patients and those experiencing arterial thrombosis as the presenting manifestation. Larger and prospective studies are needed to confirm these findings."

Clinical • Cardiovascular • CNS Disorders • Genetic Disorders • Hematological Disorders • Immunology • Ischemic stroke • Mental Retardation • Obstetrics • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Psychiatry • Renal Disease • Retinal Vein Occlusion • Rheumatology • Thrombosis

COMPARATIVE EVALUATION OF THE PERFORMANCE OF REVISED SAPPORO AND 2023 ACR/EULAR CLASSIFICATION CRITERIA IN PAEDIATRIC ONSET ANTIPHOSPHOLIPID SYNDROME - A SINGLE CENTRE COHORT WITH LONG-TERM FOLLOW-UP (EULAR 2025) - "For APS manifestations, 8/12 cases were treated with aspirin and warfarin and 2/12 with direct oral anticoagulants (DOACs). The 2023 ACR/EULAR classified 75%, while the revised Sapporo criteria classified 66% of AYA with APS diagnosed by expert opinion, suggesting that childhood-specific criteria may be warranted. In this small cohort, macrovascular thrombosis affected 66% of AYA diagnosed with APS, and 33% had more than one major thrombotic event. Overall, 47% (8/17) of AYA with persistently elevated aPL had thrombosis, despite previous publications suggesting low thrombosis risk in childhood APS."

Clinical • Cardiovascular • Dermatomyositis • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Myositis • Pediatrics • Rheumatology • Systemic Lupus Erythematosus • Thrombosis

CLINICAL-IMMUNOLOGICAL PROFILING AND PREDICTORS OF THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME: DATA FROM A DEDICATED CLINIC AT A TERTIARY CENTRE (EULAR 2025) - "Anticoagulation was used in 73 patients (86.9%), most often with vitamin K antagonists (VKA) in 57 patients (67.9%); low-dose aspirin (LDA) was used in 53 patients (63.9%) and combined antiplatelet/anticoagulant therapy in 16 patients (19.0%). Hydroxychloroquine (HCQ) was prescribed to 44 patients (52.4%) - 32/84 (38.1%) had an inflammatory rheumatic disease, of which 22/84 (26.2%) was SLE... In APS patients, arterial thrombosis and the risk of thrombotic recurrence were linked to CV comorbidities, namely dyslipidemia, highlighting the need for tight control of these comorbidities. HCQ exhibited a trend to be protective for arterial thrombosis, namely in those patients fulfilling the new and more specific updated classification criteria."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Metabolic Disorders • Obesity • Obstetrics • Pulmonary Embolism • Respiratory Diseases • Rheumatology • Systemic Lupus Erythematosus • Thrombosis

The prevalence of major bleeding at delivery in pregnant women with systemic lupus erythematosus is low -prospective cohort study. (EULAR 2025) - "There is a deep concern that a protective therapy for vascular events and/or preeclampsia (PE) with low-dose acetylsalicylic acid (LDASA) or in combination with low-molecular-weight heparin (LMWH) may be related to major bleeding (MB) at delivery... Our study displays a low prevalence of major bleeding at delivery among pregnant women with SLE, despite antithrombotic prophylaxis. Further studies with larger cohorts are needed to explore further the risk factors of pregnancy complications in patients with SLE."

Clinical • Cardiovascular • Glomerulonephritis • Gynecology • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus

Impact of GLP-1 Receptor Agonists on Major Adverse Cardiovascular Events in Ankylosing Spondylitis: A Retrospective Cohort Study (EULAR 2025) - "We employed propensity score matching for age, sex, race/ethnicity, and comorbidities (diabetes mellitus, hypertension, tobacco use) and medication use (DMARDs, biologics, anti-diabetic medications, aspirin, ACE inhibitors, ARBs, beta-blockers, diuretics, and statins)...After propensity score matching, 4,762 patients were included from both groups, balancing most baseline characteristics, though subtle differences in age, sex, and empagliflozin use persisted... Our research suggests that ankylosing spondylitis patients receiving GLP-1 receptor agonists have a lesser risk for stroke, CKD progression, and MACE compared to those not on GLP-1 receptor agonists. Prospective research with longer follow-ups is essential in confirming the above findings and exploring potential contributing factors."

Adverse events • Retrospective data • Ankylosing Spondylitis • Back Pain • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hypertension • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lumbar Back Pain • Metabolic Disorders • Musculoskeletal Pain • Myocardial Infarction • Nephrology • Ocular Inflammation • Ophthalmology • Pain • Psoriasis • Renal Disease • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Uveitis

Assessing Gout Risk Associated with GLP-1 Therapy in Obese Patients with Type 2 Diabetes: A Retrospective Cohort Study (EULAR 2025) - "Key comorbidities and medication use including hypertension, chronic kidney disease, dyslipidemia, diuretic, NSAID, and aspirin use were also similar. This study highlights the multifaceted impact of GLP-1 analogue use in patients with obesity and type 2 diabetes. GLP-1 therapy was associated with a modestly higher risk of gout and greater colchicine use, potentially reflecting the risk involved with GLP-1 use and its effect on uric acid metabolism. Despite this, GLP-1 use demonstrated significant benefits, including reduced all-cause mortality, and its known positive effect on weight and blood sugar levels underlining its effectiveness as a therapeutic option."

Retrospective data • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Genetic Disorders • Gout • Hypertension • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Rheumatology • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Predictors of adverse pregnancy outcomes in Patients with Antiphospholipid Syndrome in the French Prospective Study GR2. (EULAR 2025) - "Treatment included low-dose aspirin (n=252; 98.0%), low-molecular-weight heparin (n=251; 97.7%), and hydroxychloroquine (n=145; 56.4%) including 59 in case of associated SLE. This is the largest prospective study on predictors of APO in women with definite APS. Despite the majority of women being treated, the rate of adverse pregnancy outcomes remains high at 14.8%. Presence of lupus anticoagulant was the main predictor of APO."

Adverse events • Clinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Renal Disease • Rheumatology • Small for Gestational Age • Systemic Lupus Erythematosus • Thrombosis

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single arm, open-label, phase 2 trial (EULAR 2025) - P2 | "Background: Antiphospholipid syndrome (APS) is an autoimmune disorder associated with placenta-mediated adverse pregnancy outcomes (APO), including fetal death, preeclampsia, and fetal growth restriction, despite standard treatment with low molecular weight heparin (LMWH) plus low dose aspirin (LDA). This is the first prospective treatment trial in pregnant patients using an immunomodulatory agent to prevent APOs. The study met pre-determined criteria for efficacy of certolizumab and suggests that the addition of certolizumab pegol treatment to standard of care regimen can improve pregnancy outcomes in APS patients. Studies to determine whether TNF-α blockade prevents placenta-mediated adverse outcomes in other at-risk populations are warranted."

Adverse events • Clinical • P2 data • Genetic Disorders • Gynecology • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Obstetrics • Oncology

Low-dose Aspirin for Cardiovascular Disease Primary Prevention at Giant Cell Arteritis Diagnosis: Emulation of a Target Trial in the French Healthcare Data System (SNDS) (EULAR 2025) - "Despite an early increased risk of MACE in GCA, LDA did not reduce events at 1 year and was associated with an increased risk of major hemorrhages. At 3 years, we observed a benefit of LDA in reducing MACE and all-cause mortality, similar the findings of a large randomized trial on CVD primary prevention with LDA, conducted in younger, GCA-free diabetic patients[3]. Subgroup analyses will further identify GCA populations that may benefit most from aspirin treatment."

Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Diabetes • Dyslipidemia • Giant Cell Arteritis • Hypertension • Immunology • Ischemic stroke • Metabolic Disorders • Musculoskeletal Pain • Myocardial Infarction • Ocular Inflammation • Oncology • Ophthalmology • Optic Neuritis • Pain • Rheumatology

RESPIRATORY MANIFESTATIONS IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS VERSUS EOSINOPHILIC ASTHMA: A CASE–CONTROL STUDY (EULAR 2025) - "46.4% of EGPA subjects vs 91.2% of EA subjects (p<0.0001) were atopic (i.e. positive prick test and/or blood specific IgE for respiratory allergens), and 44.3% vs 13.4% had aspirin hypersensitivity (p<0.0001)... Compared to EA, EGPA patients at diagnosis have a different profile of respiratory manifestations, substantially higher levels of PBE, and higher proportion of patients using OCS. In this case-control study, those patients who had rhinosinusitis, any chest X-ray abnormalities, and pulmonary infiltrates, compared with those that did not, had significantly greater odds of having EGPA. Surprisingly, no significant odds were found for severe asthma and surgery for nasal polyps, challenging the common assumption that patients with severe asthma and/or rhinosinusitis may be at higher risk of developing EGPA."

Clinical • Asthma • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Langerhans Cell Histiocytosis • Nasal Polyps • Otorhinolaryngology • Rare Diseases • Respiratory Diseases • Rheumatology • Sinusitis • Vasculitis • MPO

Efficacy of therapeutic interventions for idiopathic recurrent pregnancy loss: a systematic review and network meta-analysis. (PubMed, Front Med (Lausanne)) - "The three best-ranked interventions for miscarriage rate were prednisone plus progesterone plus aspirin (SUCRA = 81%), hydroxychloroquine (SUCRA = 79%), and intralipid (SUCRA = 65%). Our results suggest that none of the analyzed interventions led to improvements in the live birth rate or a reduction in the miscarriage rate in women with idiopathic RPL. https://www.crd.york.ac.uk/prospero, identifier CRD42023455668."

Journal • Retrospective data • Review

Characterizing pharmacobezoar formation: a descriptive analysis from VigiBase. (PubMed, Clin Toxicol (Phila)) - "The most frequently involved drugs were carbidopa/levodopa (n = 148; 23.4%), quetiapine (n = 63; 10.0%), sucralfate (n = 46; 7.3%), nifedipine (n = 41; 6.5%), and acetylsalicylic acid (n = 40; 6.3%)...Almost all were serious (n = 156; 98.7%), with quetiapine, venlafaxine, ibuprofen, acetylsalicylic acid, paracetamol, and lorazepam most frequently reported...While pharmacobezoars are rare, their association with serious and potentially fatal outcomes warrants increased clinical awareness. Early recognition and appropriate management may be particularly important in cases involving high-risk drugs."

Journal • CNS Disorders • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease • Psychiatry

Competing fragmentation processes of O-acetyl-substituted carboxylate anions subjected to collision-induced dissociation. (PubMed, Eur J Mass Spectrom (Chichester)) - "Decarboxylation was observed for deprotonated O-acetylmandelic acid, whereas deprotonated acetoxyacetic acid and acetylsalicylic acid fragmented by two competing pathways...The different fragmentation behavior exhibited by O-acetyl mandelate was attributed to the charge stabilizing properties of the phenyl substituent that facilitated decarboxylation. Thus, the fragmentation processes observed depended on the structures of the O-acetyl-substituted carboxylate ions and the associated intramolecular interactions."

Journal

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications. (PubMed, Diabetes Obes Metab) - "We additionally outline clinical strategies to reduce ASCVD risk in individuals with elevated Lp(a), including lifestyle optimisation, statin therapy, PCSK9 inhibitors, and aspirin in select populations...As precision medicine advances, Lp(a) represents both a critical risk factor and a promising therapeutic target. Broader implementation of Lp(a) testing, particularly in high-risk individuals, will help improve ASCVD prevention efforts."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Hematological Disorders • Inflammation • Thrombosis

Omalizumab Efficacy in Chronic Rhinosinusitis Patients with Recurrent Nasal Polyps: An open-label, single-center, randomized, controlled study. (PubMed, Ann Otol Rhinol Laryngol) - "Omalizumab is an effective treatment for CRSwNP, significantly improving the quality of life of patients post-surgery, especially TNSS score, and reducing regeneration of polyp tissue and relapse frequency in nasal endoscopy."

Journal • Allergy • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis